ArticleJournal of biological engineering2025
A single-tube RAA-CRISPR-Cas12a diagnostic platform for rapid detection of Chlamydia trachomatis.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chlamydia trachomatis, a pathogen of global public health importance, is prioritized by the World Health Organization as a major sexually transmitted infection. Its continued worldwide spread poses persistent challenges to reproductive health and disease control systems, underscoring the urgent need for rapid and accurate diagnostic methods. While current clinical diagnosis primarily relies on nucleic acid amplification tests (NAATs), their dependence on expensive thermal cyclers, complex laboratory setups, and sophisticated procedures limits widespread use in low-resource settings. Recent advances in recombinase-aided amplification (RAA) combined with CRISPR-Cas12a have revolutionized molecular diagnostics. This study established an integrated one-tube CRISPR fluorescence detection system by combining rapid nucleic acid lysis, isothermal amplification, and CRISPR-Cas12a cleavage. The system is coupled with a portable palm-sized 4-channel fluorescence detector and a terminal app for visual readout. Experimental results demonstrated a detection limit of 10¹ copies/mL with no cross-reactivity to common reproductive tract pathogens including Neisseria gonorrhoeae, Ureaplasma urealyticum, Candida albicans, Trichomonas vaginalis, and Gardnerella vaginalis. Clinical validation against qPCR showed 100.00% sensitivity (95% CI: 87.66–100.00%), 98.31% specificity (95% CI: 90.91–99.96), 98.85% overall agreement (95% CI: 93.76– 99.97), 96.55% positive predictive value (95% CI: 80.04–99.49), and 100.00% negative predictive value (95% CI: 93.84–100.00%).This successfully developed CRISPR-Cas12a-based rapid detection method offers simple operation and fast results – complete within 30 min using rapid lysis (5 min nucleic acid release, 20 min RAA amplification, and 5 min CRISPR cleavage) – making it suitable for primary care and field screening, thereby providing a novel strategy for early diagnosis of C. trachomatis infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.